Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class.
Jean Kim, Tiffany R. Farchione, Andrew Potter, Qi Chen, R. Temple
New England Journal of Medicine May 22, 2019 DOI: 10.1056/nejmp1903305 via Semantic Scholar
Summary
AI-generated from the abstractThe FDA has approved esketamine as a new antidepressant for treatment-resistant depression. The drug offers a rapid onset of action, a key advantage for patients who have not responded to other treatments. The approval followed an evaluation of the drug's benefits and risks by the agency.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Intervention | Esketamine |
| Keywords | Medicine |
| Key finding | The FDA approved esketamine for treatment-resistant depression, citing its rapid onset of action. |
Abstract
Esketamine for Treatment-Resistant Depression The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression. The agency weighed the drug’s rapid onset...